Drug intelligence / Profile preview

IASO104

Development stage: Phase 1
Lead developer: Reindeer Biotech
Modality: Gene Addition/Replacement → Gene Therapies, Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IASO104 is a fully human B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy. It is an autologous immunotherapy where a patient's own T-cells are genetically modified to express a CAR that recognizes and binds to BCMA, a protein highly expressed on the surface of malignant plasma cells. Developed by the Institute of Hematology & Blood Diseases Hospital in China, IASO104 is being investigated for the treatment of relapsed or refractory plasma cell neoplasms, including multiple myeloma and plasma cell leukemia. The therapy aims to induce a targeted immune response against cancer cells, leading to their destruction.

Other names: Fully human BCMA-targeted chimeric antigen receptor autologous T-cell injection

Targets

BCMA (B-cell maturation antigen)

Beyond the preview

Go deeper on IASO104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IASO104.

Explore the full profile